CG Oncology Statistics

Total Valuation

CG Oncology has a market cap or net worth of $2.01 billion. The enterprise value is $1.27 billion.

Market Cap	2.01B
Enterprise Value	1.27B

Important Dates

The last earnings date was Friday, March 28, 2025, before market open.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

CG Oncology has 76.22 million shares outstanding. The number of shares has increased by 1,466.47% in one year.

Current Share Class	76.22M
Shares Outstanding	76.22M
Shares Change (YoY)	+1,466.47%
Shares Change (QoQ)	+2.84%
Owned by Insiders (%)	1.03%
Owned by Institutions (%)	84.02%
Float	60.77M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1,767.91
Forward PS	2,924.69
PB Ratio	2.74
P/TBV Ratio	2.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1,116.67
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 35.30, with a Debt / Equity ratio of 0.00.

Current Ratio	35.30
Quick Ratio	34.76
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -19.18% and return on invested capital (ROIC) is -15.60%.

Return on Equity (ROE)	-19.18%
Return on Assets (ROA)	-15.02%
Return on Invested Capital (ROIC)	-15.60%
Return on Capital Employed (ROCE)	-15.63%
Revenue Per Employee	$18,672
Profits Per Employee	-$1.44M
Employee Count	61
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -35.56% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-35.56%
50-Day Moving Average	27.92
200-Day Moving Average	32.62
Relative Strength Index (RSI)	45.35
Average Volume (20 Days)	781,368

Short Selling Information

The latest short interest is 7.23 million, so 9.48% of the outstanding shares have been sold short.

Short Interest	7.23M
Short Previous Month	7.00M
Short % of Shares Out	9.48%
Short % of Float	11.90%
Short Ratio (days to cover)	11.70

Income Statement

In the last 12 months, CG Oncology had revenue of $1.14 million and -$88.04 million in losses. Loss per share was -$1.41.

Revenue	1.14M
Gross Profit	-80.96M
Operating Income	-114.67M
Pretax Income	n/a
Net Income	-88.04M
EBITDA	-114.63M
EBIT	-114.67M
Loss Per Share	-$1.41

Full Income Statement

Balance Sheet

The company has $742.00 million in cash and $238,000 in debt, giving a net cash position of $741.76 million or $9.73 per share.

Cash & Cash Equivalents	742.00M
Total Debt	238,000
Net Cash	741.76M
Net Cash Per Share	$9.73
Equity (Book Value)	733.38M
Book Value Per Share	9.63
Working Capital	732.84M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$78.71 million and capital expenditures -$234,000, giving a free cash flow of -$78.95 million.

Operating Cash Flow	-78.71M
Capital Expenditures	-234,000
Free Cash Flow	-78.95M
FCF Per Share	-$1.04

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-10,067.25%
Pretax Margin	-7,729.50%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CG Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,466.47%
Shareholder Yield	n/a
Earnings Yield	-4.37%
FCF Yield	-3.92%

Analyst Forecast

The average price target for CG Oncology is $65.11, which is 146.44% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$65.11
Price Target Difference	146.44%
Analyst Consensus	Strong Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	288.22%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CG Oncology has an Altman Z-Score of 67.66 and a Piotroski F-Score of 3.

Altman Z-Score	67.66
Piotroski F-Score	3